Sort
4,870 grants matching “glp 1”
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists
$690,558Konrad Talbot · Loma Linda University · R01 · FY2020 · AG
Alpha- to Beta-Cell Communication in Health and Disease
$690,296Jonathan E Campbell · Duke University · R01 · FY2025 · DK
Evaluation of the entero-insular (incretin) axis in cystic fibrosis-competitive renewal.
$689,687Andrea Bridget Kelly · Children'S Hosp Of Philadelphia · R01 · FY2021 · DK
Developing robust anti-Obesity Medication ImplemeNtatiOn approaches to maximize population health (the DOMINO study)
$688,864Matthew L Maciejewski · Duke University · R01 · FY2025 · DK
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans with Prediabetes
$688,675Absalon Dennis Gutierrez · University Of Texas Hlth Sci Ctr Houston · R01 · FY2022 · DK
Affordable oral delivery of human blood protein drugs bioencapsulated in plant cells
$688,310Henry Daniell · University Of Pennsylvania · R01 · FY2017 · HL
Optimization of Substituted Phenoxyalkyl Pyridinium Oximes as Therapies for Organophosphate Poisoning
$688,206Janice E. Chambers · Mississippi State University · U01 · FY2022 · NS
Development of RNAi based sFLT1-targeting therapeutics for treatment of Preeclampsia
$687,791Anastasia Khvorova · Univ Of Massachusetts Med Sch Worcester · R01 · FY2019 · HD
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
$686,053Katherine N Cahill · Vanderbilt University Medical Center · U01 · FY2025 · AI
Core D: Biomarkers, Genomics & Epigenomics Core
$685,976Isaac Kirubakaran Sundar · Roswell Park Cancer Institute Corp · U54 · FY2019 · CA
Development of RNAi based sFLT1-targeting therapeutics for treatment of Preeclampsia
$685,210Anastasia Khvorova · Univ Of Massachusetts Med Sch Worcester · R01 · FY2017 · HD
Comparative Effectiveness of Two Initial Combination Therapies in Patients with New Onset Diabetes
$684,914Muhammad Abdul-Ghani · University Of Texas Hlth Science Center · R01 · FY2024 · DK
Comparative Effectiveness of Two Initial Combination Therapies in Patients with New Onset Diabetes
$684,914Muhammad Abdul-Ghani · University Of Texas Hlth Science Center · R01 · FY2025 · DK
Clinical and economic value of novel diabetes medications for prevention of cardiovascular disease in type 2 diabetes
$684,540Bart Ferket · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · HL
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists
$684,515Konrad Talbot · Loma Linda University · R01 · FY2021 · AG
Pathogenesis of youth onset pre-diabetes and Type 2 diabetes
$684,085Sonia Caprio · Yale University · R01 · FY2025 · DK
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists
$684,076Konrad Talbot · Loma Linda University · R01 · FY2022 · AG
Reduced Carbohydrate Diet Intervention for PCOS
$683,726Barbara A. Gower · University Of Alabama At Birmingham · R01 · FY2010 · HD
RBP2 Biology and Pathobiology
$682,891William S Blaner · Columbia University Health Sciences · R01 · FY2023 · DK
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists
$682,885Konrad Talbot · University Of California Los Angeles · R01 · FY2018 · AG
Evaluation of the entero-insular (incretin) axis in cystic fibrosis-competitive renewal.
$682,845Andrea Bridget Kelly · Children'S Hosp Of Philadelphia · R01 · FY2022 · DK
Clinical and economic value of novel diabetes medications for prevention of cardiovascular disease in type 2 diabetes
$682,248Bart Ferket · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · HL
Prostanoid modulators that reduce brain injury and inflammation after seizures
$681,405Raymond J Dingledine · Emory University · U01 · FY2010 · NS
Targeting GLP-1 receptor as a new chronotherapy against nondipping blood pressure in diabetes
$681,332Ming C Gong · University Of Kentucky · R01 · FY2024 · HL
Development of a novel class of immunotherapeutic antibody for metastatic prostate cancer
$681,039Jennifer D Wu · Cancure, Llc · R44 · FY2020 · CA